Los Angeles Capital Management LLC Has $52.54 Million Stock Holdings in Insulet Corporation $PODD

Los Angeles Capital Management LLC lifted its stake in shares of Insulet Corporation (NASDAQ:PODD) by 518.0% in the second quarter, Holdings Channel.com reports. The fund owned 167,231 shares of the medical instruments supplier’s stock after acquiring an additional 140,169 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Insulet were worth $52,541,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Metis Global Partners LLC lifted its holdings in shares of Insulet by 6.4% in the 2nd quarter. Metis Global Partners LLC now owns 3,842 shares of the medical instruments supplier’s stock worth $1,207,000 after purchasing an additional 230 shares in the last quarter. Penserra Capital Management LLC bought a new position in shares of Insulet during the 2nd quarter worth $67,000. Golden State Wealth Management LLC grew its stake in Insulet by 202.9% in the 2nd quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock valued at $32,000 after buying an additional 69 shares in the last quarter. Andra AP fonden lifted its holdings in shares of Insulet by 167.9% in the second quarter. Andra AP fonden now owns 57,600 shares of the medical instruments supplier’s stock worth $18,097,000 after buying an additional 36,100 shares in the last quarter. Finally, Resona Asset Management Co. Ltd. boosted its holdings in Insulet by 7.6% in the 2nd quarter. Resona Asset Management Co. Ltd. now owns 25,589 shares of the medical instruments supplier’s stock valued at $8,034,000 after purchasing an additional 1,803 shares during the period.

Insulet Trading Down 1.1%

Insulet stock opened at $319.82 on Friday. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. Insulet Corporation has a 52-week low of $230.05 and a 52-week high of $353.50. The company has a market cap of $22.51 billion, a P/E ratio of 97.21, a P/E/G ratio of 2.64 and a beta of 1.39. The business has a 50-day simple moving average of $325.06 and a two-hundred day simple moving average of $309.40.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm had revenue of $521.70 million during the quarter, compared to the consensus estimate of $678.70 million. During the same quarter in the previous year, the firm posted $1.08 EPS. The company’s revenue for the quarter was up 29.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Analysts predict that Insulet Corporation will post 3.92 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Oppenheimer raised their price objective on shares of Insulet from $324.00 to $365.00 and gave the company an “outperform” rating in a research report on Monday, September 8th. Zacks Research raised shares of Insulet from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 14th. Truist Financial boosted their target price on Insulet from $365.00 to $390.00 and gave the company a “buy” rating in a research note on Friday. Jefferies Financial Group raised their target price on shares of Insulet from $375.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Raymond James Financial lifted their price target on Insulet from $360.00 to $366.00 and gave the company an “outperform” rating in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $368.80.

Insider Buying and Selling

In other news, SVP Laetitia Cousin sold 797 shares of the stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the sale, the senior vice president directly owned 3,890 shares of the company’s stock, valued at $1,356,870.90. This represents a 17.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Prem Singh sold 687 shares of the firm’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the sale, the senior vice president owned 3,456 shares in the company, valued at $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.39% of the company’s stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.